Array ( [urn:ac.highwire.org:guest:identity] => Array ( [runtime-id] => urn:ac.highwire.org:guest:identity [type] => guest [service-id] => ajnr-ac.highwire.org [access-type] => Controlled [privilege] => Array ( [urn:ac.highwire.org:guest:privilege] => Array ( [runtime-id] => urn:ac.highwire.org:guest:privilege [type] => privilege-set [privilege-set] => GUEST ) ) [credentials] => Array ( [method] => guest ) ) ) 1naresh

Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)

PPV and NPV for time-of-flight MR imaging as a screening test for complete obliteration for various disease-prevalence values^a
Disease Prevalence PPV NPV
0.1 30.8% 95.2%
0.2 50.0% 89.8%
0.3 63.2% 83.7%
0.4 72.7% 76.7%
0.5 80.0% 68.8%
0.6 85.7% 59.5%
0.667^b 88.9% 52.3%
0.7 90.3% 48.5%

 ↵a Disease prevalence represents the pretest probability of complete obliteration without the time-of-flight MR imaging results. PPV represents the posttest probability of complete obliteration based on a screening test with 61.5% sensitivity and 84.6% specificity.

 ↵b Sample estimate by reader 1 was 67% (78/117) in Buis et al.¹

Disease Prevalence	PPV	NPV
0.1	30.8%	95.2%
0.2	50.0%	89.8%
0.3	63.2%	83.7%
0.4	72.7%	76.7%
0.5	80.0%	68.8%
0.6	85.7%	59.5%
0.667^b	88.9%	52.3%
0.7	90.3%	48.5%